華錄百納(300291.SZ)擬變更部分募集資金實施主體及用途、使用節餘募集資金
格隆匯12月11日丨華錄百納(300291.SZ)公佈,公司於2020年12月11日召開第四屆董事會第十四次會議和第四屆監事會第十一次會議,審議通過了《關於變更部分募集資金實施主體及用途、使用節餘募集資金的議案》:同意公司變更“影視內容製作”子項目電視劇《燦爛的你》、電影《牽手之後》、《浮生若夢》的實施主體;變更“綜藝節目製作”項目尚未使用的募集資金共計1.05億元的用途,用於投資“影視內容製作”電視劇子項目,變更金額佔總籌資金淨額的4.81%;將部分電視劇項目的節餘募集資金共計6312.63萬元投入電視劇《逆光者》、《先生請立正》,節餘資金佔總籌資金淨額的2.91%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.